Curcumin Inhibition of DYRK Kinases

Voices Powered byElevenlabs logo
Connected to paperThis paper is a preprint and has not been certified by peer review

Curcumin Inhibition of DYRK Kinases


Menezes, F.; Grygier, P.; Pustelny, K.; Popowicz, G. M.; Czarna, A.


Curcumin is known as a dietary supplement with several health benefits, including antioxidant, blood sugar-lowering, anti-inflammatory, and anti-cancer properties. These benefits make it useful in the treatment of diabetes, neurodegenerative diseases, and cancer. This research focuses on how curcumin interacts with dual-specificity tyrosine-regulated kinases (DYRKs), particularly DYRK1A and DYRK2, which control important cellular processes such as protein breakdown, gene activity and DNA packaging. DYRK1A is crucial for the growth and survival of pancreatic {beta}-cells, which are key in the treatment of diabetes. Curcumin helps increase insulin release and sensitivity by affecting these cells. DYRK2, on the other hand, is involved in cancer, where curcumin\'s ability to block its activity helps to reduce tumour growth and spread. These interactions demonstrate curcumin\'s potential as a versatile treatment option. By affecting DYRK1A and DYRK2, curcumin promotes {beta}-cell health in diabetes and fights cancer by inhibiting cell growth and promoting cell death. This study underscores the promise of curcumin as a natural compound for treating complex diseases associated with oxidative stress and inflammation, highlighting the need for a better understanding of DYRK kinases to effectively exploit their role in disease processes and cell signalling.

Follow Us on


Add comment